Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong financial performance with 16% EPS growth and improved margins. Despite challenges in Greater China, the overall growth outlook is optimistic, especially with high single-digit revenue growth and strategic transitions like NovaSeq X. The Q&A reveals confidence in achieving long-term targets and strong demand in clinical markets. The lack of detailed M&A criteria and cautious guidance for 2026 are minor concerns, but the positive aspects outweigh these, suggesting a positive stock price movement.
Key Financial Performance
Revenue Illumina's revenue for Q4 2025 was $1.16 billion, up 5% year-over-year on a reported basis and 4% on a constant currency basis. Excluding Greater China, revenue was up 7% year-over-year. The increase was driven by strength in clinical consumables revenue, better-than-expected NovaSeq X placements, and outperformance in China. A small benefit from year-end budget purchasing also contributed.
Clinical Consumables Revenue Clinical consumables revenue grew 20% year-over-year in Q4 2025 outside of China. This growth was driven by broader adoption of NGS-based testing and customers converting current assays to ones requiring more sequencing data, such as transitions from whole exome to whole genome sequencing in oncology and genetic disease.
Sequencing Consumables Revenue Sequencing consumables revenue was $755 million in Q4 2025, up 8% year-over-year and 11% excluding China. High-throughput volume growth and increased utilization of NovaSeq X instruments contributed to this growth.
Sequencing Instruments Revenue Sequencing instruments revenue was $154 million in Q4 2025, approximately flat year-over-year and up 3% excluding China. Strong placements of NovaSeq X and MiSeq i100 instruments drove this performance.
Non-GAAP Operating Margins Non-GAAP operating margins expanded by 180 basis points year-over-year in 2025. This improvement was attributed to cost optimization measures and increased operating leverage from a better cost structure.
Non-GAAP EPS Non-GAAP EPS grew 16% year-over-year in 2025, reaching $4.84. This growth was driven by higher revenue, improved margins, and disciplined cost management.
Free Cash Flow Free cash flow for Q4 2025 was $267 million, and for the full year, it was $931 million. This strong cash flow performance was supported by higher revenue and disciplined capital expenditures.
Greater China Revenue Greater China revenue was $55 million in Q4 2025, representing a $25 million decline from Q4 2024. Export restrictions impacted the instruments business, which was down 55% in the region.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NovaSeq X: Strong instrument sales with Q4 being the second highest quarterly placements since its launch in 2023. It supports durable growth in core sequencing business.
Illumina Connected Multiomics: Launched to integrate and interpret data across different data types, simplifying multiomic analysis and making workflows more scalable.
BioInsight: Launched to expand discovery and drug development through data, software, and AI. Introduced the Billion Cell Atlas, a comprehensive map of human biology for drug discovery.
Spatial transcriptomics solution and constellation mapped-read technology: Expected to launch in the first half of 2026, extending integrated workflows for research and clinical settings.
Clinical consumables: Achieved 20% growth ex-China in Q4 2025, driven by adoption of sequencing-based diagnostic tests and broader demand for genomic profiling.
Proteomics: Strengthened position with the acquisition of SomaLogic, enhancing capabilities in protein analysis and multiomics.
Biopharma partnerships: Announced collaborations with AstraZeneca, Merck, and Eli Lilly for the Billion Cell Atlas, indicating growing engagement in data-driven drug discovery.
Operating margins: Expanded non-GAAP operating margins by 180 basis points in 2025 and projected further expansion in 2026.
Cost optimization: Achieved significant cost reductions, contributing to improved financial performance.
Revenue growth: Returned to growth in 2025 with 2% ex-China revenue growth for the year and 7% in Q4.
Core sequencing: Focused on high-throughput, high-quality sequencing with NovaSeq X as the anchor product.
Scaling multiomics: Building integrated solutions through internal development and acquisitions like SomaLogic.
Expanding services, data, and software: Launched BioInsight and Illumina Connected Multiomics to enhance capabilities in data-driven research and clinical applications.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
China Revenue Decline: Revenue from Greater China declined by $25 million year-over-year in Q4 2025, and the instruments business in China was down 55% due to export restrictions. This poses a significant challenge to revenue growth in the region.
Research Market Uncertainty: Research and applied consumables sales were flat year-over-year, with continued uncertainty in the funding environment and pricing dynamics related to the NovaSeq X transition. This could hinder growth in the research segment.
Export Restrictions in China: Export restrictions in China have significantly impacted instrument sales, with little or no expected improvement in the first half of 2026. This creates a headwind for revenue growth in the region.
Pricing Headwinds from NovaSeq X Transition: The transition to NovaSeq X has created pricing headwinds, particularly in the research market, which are expected to persist until the transition is substantially complete by the end of 2026.
Dependence on Clinical Market Growth: The company’s growth is heavily reliant on the clinical market, which grew 20% ex-China in Q4 2025. Any slowdown in clinical market adoption or reimbursement coverage could adversely impact growth.
Regulatory and Policy Uncertainty: Uncertainty around U.S. policy and the funding environment for research customers continues to pose risks to the research business.
SomaLogic Acquisition Integration: The recent acquisition of SomaLogic is expected to dilute EPS by $0.18 in 2026 and could pose integration challenges, impacting operating margins and financial performance.
China Instrument Import Challenges: The company faces challenges in importing instruments into China, which could limit growth opportunities in the region.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Illumina expects organic revenue growth of 2% to 4% in 2026, excluding China. Including currency impacts and the SomaLogic acquisition, reported revenue growth is projected at 4% to 6%. China sales are expected to be a 1-point headwind to total company revenue growth.
Clinical Consumables Growth: Clinical consumables are expected to grow double-digit to mid-teens in 2026, driven by strong volumes from clinical customers and adoption of sequencing-intensive whole-genome approaches.
Research and Applied Markets: Revenue from research and applied markets is expected to decline mid-to-high single digits in 2026, with continued uncertainty in the funding environment.
Instrument Sales: Instrument sales are projected to be flat to down low-single-digit year-over-year in 2026, with an average placement of 50 to 60 NovaSeq X instruments per quarter.
Operating Margins: Operating margins are expected to expand by 130 basis points in 2026, excluding the impact of the SomaLogic acquisition. Including SomaLogic, operating margins are projected to be between 23.3% and 23.5%.
Earnings Per Share (EPS): EPS guidance for 2026 is $5.05 to $5.20, including $0.18 of dilution from the SomaLogic acquisition. Excluding this dilution, EPS is expected to grow 10% year-over-year.
China Market: China sales are expected to be $210 million to $220 million in 2026, with little or no step-up in instrument sales in the first half of the year.
NovaSeq X Transition: The transition to NovaSeq X is expected to be substantially complete by the end of 2026, with pricing dynamics shifting towards new applications like whole-genome sequencing adoption.
Multiomics and Spatial Transcriptomics: Illumina plans to introduce its spatial transcriptomics solution and constellation mapped-read technology in the first half of 2026, enhancing its multiomics capabilities.
Biopharma and Drug Discovery: The company is expanding its presence in biopharma through BioInsight and the Billion Cell Atlas, with collaborations already established with AstraZeneca, Merck, and Eli Lilly.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: Illumina returned approximately $740 million to shareholders through share repurchases in 2025. Additionally, in Q4, the company repurchased 337,000 shares for approximately $42 million at an average price of $124.12 per share. At the end of the quarter, $643 million remained on the share repurchase authorization, and the company intends to continue repurchasing shares opportunistically.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Does guidance embed an assumption that you essentially end the year at 26% to 27% operating margin? Is there any change to your 2027 margin target factoring in SomaLogic?
A:The management feels confident about their long-term targets, aiming for high single-digit growth by 2027 and a 26% operating margin. They have made progress with a 200 basis point improvement last year despite headwinds and are committing to another 130 basis points. The acquisition of SomaLogic is initially dilutive, but they are working on synergies to get as close to the 26% margin as possible by 2027.
Q:How are you thinking about capital deployment, specifically M&A criteria and priorities?
A:The management did not provide specific details on M&A criteria and priorities but emphasized their commitment to stabilizing the business and generating free cash flow.
Q:What drives the step down from 6.5% exit rate in Q4 to 3% guidance for fiscal '26? Was there anything one-off about Q4?
A:Management stated that Q4 is typically a strong quarter, and the guidance reflects an average of the second half of 2025. They are not seeing a substantial step down but are cautious due to uncertainties in the research academic environment and NIH budget distribution.
Q:Can you provide the split between research and clinical instrumentation? How are you thinking about competition in the research market?
A:In Q4, more than 60% of instrument placements were clinical, and this trend is expected to continue in 2026. The research market remains muted due to macroeconomic factors, but there has been no significant change in competition.
Q:Can you delineate how much of the clinical growth is mix versus volume? What is the plan for incorporating Onso technology?
A:Clinical growth is driven by both increased volume and larger panels, such as moving from exome to whole genome. The Onso technology acquisition strengthens their portfolio, but its impact will be more meaningful in 2027 and beyond.
Q:What are the expectations for sequencing consumables and instruments in 2026?
A:High-throughput consumables, especially in clinical, are expected to perform strongly. Instrument placements are guided at 200-240 for the year, with strong demand from clinical customers.
Q:Which clinical applications (oncology or genetic) will grow faster in 2026?
A:Oncology is expected to be the main growth driver, although rare diseases are also growing at a healthy pace.
Q:What is the messaging to customers regarding the full workflow and cost-efficiency of Illumina products?
A:Illumina emphasizes the cost-efficiency and high-quality insights of their full workflow, including sequencing and library prep. They plan to highlight these advantages at the AGBT conference.
Q:What does the $100 genome price point from competitors mean for Illumina?
A:Management believes customers consider more than just price, focusing on the full workflow and quality. Illumina is confident in its ability to compete on all parameters and address market segments with different price points if needed.
Q:What are the assumptions for academic core labs in terms of investments in instruments and consumables?
A:Academic core labs have been supported despite funding challenges. The NIH budget provides better visibility, but uncertainties remain. Illumina has placed X instruments in these labs to support their needs.
Q:How is the NovaSeq 6000 pull-through holding up, and what are the growth expectations for Europe and Asia?
A:NovaSeq 6000 pull-through remains strong as customers continue using it for validated assays. Europe has shown strong growth, and APAC and EMEA regions are expected to rebound in 2026.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on M&A criteria and priorities, as well as a detailed breakdown of clinical growth between mix and volume. They also did not quantify the impact of BioInsight or provide a clear timeline for incorporating Onso technology.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Ankur
BioInsight
Cell
Conor
Director
Illumina position
QA
SomaLogic Illumina
acquisition dilution
addition
adoption
area
assay
biology
biopharma
consumables ex
core multiomics
demand
end market
ex China
example
experiment
field
genomics
milestone
model
partner
patient
pillar core
platform
policy
power
progress momentum
protein
research setting
scale
service software
software AI
software capability
success
testing
ILMN Transcript
Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call highlights strong financial performance with a 19% increase in EPS and improved margins. Management expressed optimism about clinical growth and incremental instrument placements, despite not raising organic growth guidance. The Q&A section reassures strong demand and no market freezing, with expectations of margin improvements later in the year. Although some vague responses were noted, the overall sentiment is positive with raised guidance and strategic growth in clinical and spatial markets.
Illumina, Inc. (ILMN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-3
Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript
Positive2-5
The earnings call summary and Q&A indicate strong financial performance with 16% EPS growth and improved margins. Despite challenges in Greater China, the overall growth outlook is optimistic, especially with high single-digit revenue growth and strategic transitions like NovaSeq X. The Q&A reveals confidence in achieving long-term targets and strong demand in clinical markets. The lack of detailed M&A criteria and cautious guidance for 2026 are minor concerns, but the positive aspects outweigh these, suggesting a positive stock price movement.
Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
ILMN Slides
Illumina Q4 2025 slides: Clinical growth accelerates as NovaSeq X transition advances2026-02-05
Illumina Q2 2025 slides: Revenue dips 3% while EPS grows 9% amid NovaSeq X transition2025-10-30
Illumina Q2 2025 slides: revenue declines 3% while margins expand, SomaLogic acquisition announced2025-07-31
Illumina Q1 2025 slides: Revises guidance downward amid China restrictions and tariff impacts2025-05-08
ILMN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
